SCHEMBL298694

SCHEMBL298694

CCc1c2[n+](c(Cl)c3c(OC)c(OC)ccc13)CCc1cc3c(cc1-2)OCO3

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 10/20 0.66
BCHE P06276 4/20 0.48
ACHE P22303 4/20 0.48
EP300 Q09472 3/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
MAPT P10636 2/20 0.48
CHRM1 P11229 2/20 0.48
DRD2 P14416 2/20 0.48
TSHR P16473 2/20 0.48
ADRA2B P18089 2/20 0.48
ADRA2C P18825 2/20 0.48
RXRA P19793 2/20 0.48
DRD1 P21728 2/20 0.48
HTR2B P41595 2/20 0.48
HTT P42858 2/20 0.48
RAD52 P43351 2/20 0.48
KCNH2 Q12809 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298485 0.89 P2RX7 (0.55) P2RX7BCHEACHEEP300ALDH1A1
SCHEMBL298971 0.88 P2RX7 (0.55) P2RX7BCHEACHEEP300ALDH1A1
SCHEMBL13070513 0.86 P2RX7 (0.48) P2RX7ACHELMNACYP3A4MAPT
SCHEMBL298305 0.79 P2RX7 (1.00) P2RX7BCHEACHEEP300ALDH1A1
SCHEMBL298574 0.78 BCHE (0.62) BCHEACHEEP300ALDH1A1LMNA
SCHEMBL16425963 0.75 XBP1 (0.60) P2RX7BCHEACHEEP300ALDH1A1
SCHEMBL14513590 0.75 P2RX7 (0.87) P2RX7
SCHEMBL13070786 0.75 COL1A1 (0.45) P2RX7ACHEALDH1A1LMNACYP3A4
SCHEMBL14513579 0.74 BCHE (0.60) P2RX7BCHEACHEEP300ALDH1A1
SCHEMBL14513612 0.74 P2RX7 (0.89) P2RX7BCHEACHEEP300ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427460-B1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-26 EP disclosed
EP-2427460-B1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-26 EP disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2427460-A1 NOVEL ISOQUINOLINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010128061-A1 NOVEL ISOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES CYP3A7, RAB7A, IPO7 P2RX7 669/4885BCHE 3051/4885ACHE 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.